For further product information contact :@0.078610:0.883076:0.314525:0.883076:0.314525:0.871959:0.078610:0.871959:0.007538:0.007596:0.004762:0.003528:0.004316:0.007244:0.004762:0.004751:0.007244:0.006961:0.004762:0.003528:0.007808:0.004504:0.007596:0.007808:0.007244:0.006715:0.004751:0.003528:0.003093:0.007244:0.004198:0.007596:0.004762:0.011183:0.006750:0.004751:0.003093:0.007596:0.007244:0.003528:0.006538:0.007596:0.007244:0.004751:0.006809:0.006715:0.004751:0.003528
PHARMA DYNAMICS:@0.314525:0.883552:0.437926:0.883552:0.437926:0.871753:0.314525:0.871753:0.007855:0.008937:0.009290:0.008502:0.010207:0.009290:0.003528:0.008431:0.008420:0.009290:0.009290:0.010207:0.003951:0.008678:0.007526
  P O Box  30958  Tokai  Cape Town 7966   :@0.437926:0.883076:0.689798:0.883076:0.689798:0.871959:0.437926:0.871959:0.003528:0.003528:0.007855:0.003528:0.009995:0.003528:0.008490:0.007185:0.006750:0.003528:0.003528:0.007208:0.008408:0.007549:0.007197:0.007408:0.003528:0.003528:0.006127:0.007596:0.006573:0.006809:0.003093:0.003528:0.003528:0.008678:0.006809:0.007808:0.006961:0.003528:0.006127:0.007302:0.010125:0.007244:0.003528:0.006832:0.007608:0.007608:0.007608:0.003528:0.003528:0.003528
Fax:@0.689798:0.883552:0.711046:0.883552:0.711046:0.871753:0.689798:0.871753:0.007420:0.006961:0.006867
 +27 21 701 5898:@0.711035:0.883076:0.806555:0.883076:0.806555:0.871959:0.711035:0.871959:0.003528:0.007350:0.006903:0.007009:0.003528:0.007044:0.004210:0.003528:0.006773:0.008349:0.004210:0.003528:0.007197:0.007350:0.007608:0.007408
Email:@0.078610:0.894454:0.111724:0.894454:0.111724:0.882654:0.078610:0.882654:0.007879:0.011171:0.006961:0.003551:0.003551
 info@pharmadynamics.co.za  :@0.111724:0.893978:0.289007:0.893978:0.289007:0.882861:0.111724:0.882861:0.003528:0.003093:0.007244:0.004198:0.007596:0.011524:0.007808:0.007244:0.006809:0.004762:0.011183:0.006809:0.007808:0.006950:0.007244:0.006809:0.011183:0.003093:0.006715:0.005856:0.002646:0.006538:0.007361:0.002881:0.006538:0.006809:0.003528:0.003528
CUSTOMER CARE LINE:@0.289007:0.894454:0.427578:0.894454:0.427578:0.882654:0.289007:0.882654:0.008678:0.008890:0.007350:0.007267:0.009995:0.010207:0.007879:0.008502:0.003528:0.008678:0.009290:0.008502:0.007879:0.003528:0.007279:0.003951:0.009290:0.007879
 0860 PHARMA (742 762) / +27 21 707 7000  :@0.427578:0.893978:0.697206:0.893978:0.697206:0.882861:0.427578:0.882861:0.003528:0.008408:0.007408:0.007608:0.008408:0.003528:0.007855:0.008937:0.009290:0.008502:0.010207:0.009290:0.003528:0.005104:0.006009:0.007890:0.007044:0.003528:0.006773:0.007608:0.007044:0.005104:0.003528:0.005974:0.003528:0.007350:0.006903:0.007009:0.003528:0.007044:0.004210:0.003528:0.006773:0.008067:0.007009:0.003528:0.006773:0.008408:0.008408:0.008408:0.003528:0.003528
www.pharmadynamics.co.za:@0.697206:0.894454:0.865963:0.894454:0.865963:0.882654:0.697206:0.882654:0.010007:0.010007:0.009302:0.003363:0.007937:0.007326:0.006961:0.004915:0.011171:0.006961:0.007937:0.007056:0.007326:0.006961:0.011171:0.003551:0.006715:0.005903:0.003128:0.006538:0.007573:0.003363:0.006620:0.006961
PEARINDA 4, 8.:@0.078610:0.906329:0.143673:0.906329:0.143673:0.897208:0.078610:0.897208:0.005483:0.005322:0.005947:0.005816:0.002812:0.005997:0.005896:0.005604:0.003568:0.005100:0.002419:0.003568:0.005110:0.002419
 Each tablet contains 4, 8 mg perindopril :@0.143673:0.906237:0.310224:0.906237:0.310224:0.897432:0.143673:0.897432:0.003568:0.005020:0.004626:0.004435:0.004667:0.003568:0.002933:0.004677:0.004808:0.002187:0.004697:0.002611:0.003568:0.004505:0.004667:0.004888:0.002933:0.004657:0.002167:0.004838:0.004102:0.003568:0.004999:0.002419:0.003568:0.004838:0.003568:0.007398:0.004667:0.003568:0.004848:0.004626:0.003205:0.002167:0.004828:0.004858:0.004667:0.004818:0.003205:0.002137:0.002056:0.002419
tert:@0.311373:0.906237:0.324375:0.906237:0.324375:0.897432:0.311373:0.897432:0.002651:0.004606:0.003135:0.002611
-butylamine respectively. S3 A41/7.1.3/0649, 0650. NAM NS2 10/7.1.3/0476, 0477. For full prescribing information, refer to the professional information :@0.324385:0.906237:0.938108:0.906237:0.938108:0.897432:0.324385:0.897432:0.003760:0.004818:0.004909:0.003054:0.004274:0.002197:0.004637:0.007358:0.002167:0.004818:0.004475:0.003568:0.003175:0.004677:0.004284:0.004848:0.004667:0.004566:0.002832:0.002238:0.004183:0.004606:0.002238:0.003891:0.002419:0.003568:0.005433:0.004838:0.003568:0.005463:0.004747:0.004969:0.003336:0.004203:0.001955:0.004566:0.002651:0.005423:0.003417:0.005241:0.005261:0.005140:0.004979:0.002419:0.003568:0.005241:0.005211:0.005191:0.004999:0.002419:0.003568:0.006098:0.005513:0.007096:0.003568:0.005957:0.005322:0.004838:0.003568:0.004667:0.005463:0.003336:0.004203:0.001955:0.004566:0.002651:0.005423:0.003417:0.005231:0.004878:0.005030:0.005040:0.002419:0.003568:0.005231:0.004878:0.005211:0.004203:0.002419:0.003568:0.004798:0.004667:0.002983:0.003568:0.002842:0.004778:0.002137:0.002056:0.003568:0.004818:0.003175:0.004677:0.004334:0.004435:0.003205:0.002167:0.004808:0.002167:0.004818:0.004667:0.003568:0.002167:0.004888:0.002812:0.004667:0.003195:0.007398:0.004677:0.002832:0.002228:0.004667:0.004818:0.002419:0.003568:0.003175:0.004697:0.002772:0.004626:0.002983:0.003568:0.002812:0.004475:0.003568:0.002852:0.004818:0.004475:0.003568:0.004818:0.003215:0.004687:0.002772:0.004677:0.004374:0.004253:0.002228:0.004667:0.004818:0.004657:0.002056:0.003568:0.002167:0.004888:0.002812:0.004667:0.003195:0.007398:0.004677:0.002832:0.002228:0.004667:0.004667:0.002419
approved by SAHPRA, April 2009. :@0.078621:0.915219:0.213986:0.915219:0.213986:0.906414:0.078621:0.906414:0.004677:0.004818:0.004818:0.003215:0.004606:0.004183:0.004647:0.004667:0.002983:0.004768:0.004092:0.002983:0.005473:0.005523:0.005765:0.005211:0.005927:0.005544:0.002419:0.002983:0.005433:0.004818:0.003205:0.002137:0.002056:0.002983:0.005140:0.005241:0.005211:0.004999:0.002419:0.002419
PEARINDA PLUS 4. :@0.214551:0.915312:0.294702:0.915312:0.294702:0.906191:0.214551:0.906191:0.005483:0.005322:0.005947:0.005816:0.002812:0.005997:0.005896:0.005604:0.002983:0.005483:0.004949:0.005705:0.005231:0.002983:0.005100:0.002419:0.002419
Each tablet contains 4 mg perindopril :@0.295266:0.915219:0.444340:0.915219:0.444340:0.906414:0.295266:0.906414:0.005020:0.004626:0.004435:0.004667:0.002983:0.002933:0.004677:0.004808:0.002187:0.004697:0.002611:0.002983:0.004505:0.004667:0.004888:0.002933:0.004657:0.002167:0.004838:0.004102:0.002983:0.004838:0.002983:0.007398:0.004667:0.002983:0.004848:0.004626:0.003205:0.002167:0.004828:0.004858:0.004667:0.004818:0.003205:0.002137:0.002056:0.002419
tert:@0.444904:0.915219:0.457907:0.915219:0.457907:0.906414:0.444904:0.906414:0.002651:0.004606:0.003135:0.002611
-butylamine and 1,25 mg indapamide. S3 A41/7.1.3/0633. NAM NS2 10/7.1.3/0611. For full prescribing information, refer :@0.457866:0.915219:0.938208:0.915219:0.938208:0.906414:0.457866:0.906414:0.003760:0.004818:0.004909:0.003054:0.004274:0.002197:0.004637:0.007358:0.002167:0.004818:0.004475:0.002983:0.004677:0.004828:0.004667:0.002983:0.004566:0.002721:0.005090:0.004838:0.002983:0.007398:0.004667:0.002983:0.002167:0.004828:0.004828:0.004677:0.004848:0.004637:0.007358:0.002197:0.004818:0.004576:0.002419:0.002983:0.005433:0.004838:0.002983:0.005463:0.004747:0.004969:0.003336:0.004203:0.001955:0.004566:0.002651:0.005423:0.003417:0.005241:0.005211:0.005201:0.005070:0.002419:0.002983:0.006098:0.005513:0.007096:0.002983:0.005957:0.005322:0.004838:0.002983:0.004667:0.005463:0.003336:0.004203:0.001955:0.004566:0.002651:0.005423:0.003417:0.005241:0.005020:0.004435:0.004566:0.002419:0.002983:0.004798:0.004667:0.002983:0.002983:0.002842:0.004778:0.002137:0.002056:0.002983:0.004818:0.003175:0.004677:0.004334:0.004435:0.003205:0.002167:0.004808:0.002167:0.004818:0.004667:0.002983:0.002167:0.004888:0.002812:0.004667:0.003195:0.007398:0.004677:0.002832:0.002228:0.004667:0.004818:0.002419:0.002983:0.003175:0.004697:0.002772:0.004626:0.002983:0.002419
to the professional information approved by SAHPRA, April 2010. :@0.078621:0.924202:0.339494:0.924202:0.339494:0.915396:0.078621:0.915396:0.002812:0.004475:0.003417:0.002852:0.004818:0.004475:0.003417:0.004818:0.003215:0.004687:0.002772:0.004677:0.004374:0.004253:0.002228:0.004667:0.004818:0.004657:0.002056:0.003417:0.002167:0.004888:0.002812:0.004667:0.003195:0.007398:0.004677:0.002832:0.002228:0.004667:0.004667:0.003417:0.004677:0.004818:0.004818:0.003215:0.004606:0.004183:0.004657:0.004667:0.003417:0.004768:0.004092:0.003417:0.005473:0.005523:0.005765:0.005211:0.005927:0.005544:0.002419:0.003417:0.005433:0.004818:0.003205:0.002137:0.002056:0.003417:0.005140:0.005030:0.004667:0.004999:0.002419:0.002419
1) :@0.340492:0.924294:0.350834:0.924294:0.350834:0.915173:0.340492:0.915173:0.004939:0.002983:0.002419
 cacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease:ﬁThe EUROPA study Investigators. “Ef :@0.351872:0.924202:0.938188:0.924202:0.938188:0.915396:0.351872:0.915396:0.002419:0.004919:0.004314:0.004727:0.004657:0.004314:0.002207:0.004778:0.003417:0.004092:0.003437:0.004626:0.002792:0.003467:0.004677:0.003417:0.004092:0.003437:0.004677:0.004818:0.004667:0.003215:0.004667:0.004505:0.003417:0.004475:0.002187:0.004808:0.004677:0.002933:0.004385:0.003417:0.004667:0.002852:0.002278:0.006723:0.003417:0.004102:0.002923:0.004888:0.004626:0.002187:0.002822:0.004677:0.004848:0.003417:0.004667:0.004818:0.004667:0.007428:0.004637:0.003417:0.004102:0.002923:0.004888:0.004626:0.004183:0.004596:0.003417:0.002983:0.004677:0.002197:0.004778:0.004435:0.004334:0.004727:0.004233:0.004606:0.002228:0.004778:0.003205:0.004677:0.004526:0.003417:0.002611:0.004687:0.003417:0.004667:0.004667:0.002228:0.002832:0.004566:0.004838:0.004798:0.004657:0.003175:0.003417:0.004667:0.002167:0.003417:0.002056:0.002137:0.003205:0.004818:0.004667:0.004858:0.004828:0.002167:0.003205:0.004626:0.004848:0.003417:0.002611:0.004687:0.003417:0.004092:0.004465:0.004626:0.004526:0.002459:0.002459:0.003195:0.004828:0.004334:0.003417:0.002419:0.004314:0.003296:0.004667:0.002812:0.004677:0.004828:0.002197:0.002832:0.004385:0.004677:0.004183:0.004778:0.002288:0.003417:0.004092:0.004878:0.004828:0.002852:0.004385:0.003417:0.005040:0.004909:0.005927:0.005503:0.005614:0.004989:0.003417:0.004475:0.004818:0.004989:0.002419
randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study)”. :@0.078621:0.933184:0.422226:0.933184:0.422226:0.924379:0.078621:0.924379:0.003256:0.004677:0.004828:0.004858:0.004626:0.007358:0.002157:0.004012:0.004657:0.004818:0.002419:0.004425:0.004858:0.004657:0.004798:0.004808:0.002187:0.004747:0.003760:0.004808:0.002137:0.002167:0.004828:0.004818:0.002419:0.004425:0.004808:0.002197:0.004626:0.004475:0.004626:0.004888:0.004798:0.003850:0.004505:0.004667:0.004888:0.002852:0.003215:0.004647:0.002137:0.002187:0.004657:0.004818:0.002419:0.004425:0.007378:0.004778:0.002278:0.002832:0.002207:0.004475:0.004626:0.004888:0.002852:0.003175:0.004475:0.004425:0.002852:0.003205:0.002197:0.004657:0.002056:0.004425:0.002863:0.002852:0.004818:0.004475:0.004425:0.004989:0.005614:0.005503:0.005927:0.004909:0.005040:0.004425:0.004385:0.002852:0.004828:0.004878:0.004495:0.002812:0.003699:0.002419:0.002419
The Lancet:@0.424232:0.933184:0.467865:0.933184:0.467865:0.924379:0.424232:0.924379:0.004576:0.004768:0.004475:0.004425:0.004445:0.004606:0.004788:0.004415:0.004526:0.002611
 2003;362:782-788. :@0.467845:0.933184:0.552723:0.933184:0.552723:0.924379:0.467845:0.924379:0.004425:0.005140:0.005241:0.005171:0.005392:0.002873:0.005201:0.005110:0.005282:0.002469:0.005050:0.005080:0.004949:0.003306:0.005050:0.005221:0.005080:0.002419:0.002419
2) :@0.554729:0.933276:0.565484:0.933276:0.565484:0.924156:0.554729:0.924156:0.005352:0.002983:0.002419
The PREAMI study Investigators. “Effects of angiotensin-converting enzyme inhibition with :@0.567510:0.933184:0.938178:0.933184:0.938178:0.924379:0.567510:0.924379:0.004989:0.004818:0.004475:0.004425:0.005211:0.005624:0.005312:0.005513:0.007439:0.002056:0.004425:0.004385:0.002852:0.004828:0.004878:0.004092:0.004425:0.002288:0.004778:0.004183:0.004677:0.004385:0.002832:0.002197:0.004828:0.004677:0.002812:0.004667:0.003296:0.004314:0.002419:0.004425:0.004334:0.004828:0.003084:0.002772:0.004667:0.004566:0.002923:0.004102:0.004425:0.004687:0.002611:0.004425:0.004677:0.004818:0.004778:0.002228:0.004687:0.002792:0.004626:0.004838:0.004253:0.002167:0.004878:0.003850:0.004505:0.004667:0.004778:0.004183:0.004626:0.003467:0.002832:0.002167:0.004818:0.004667:0.004425:0.004626:0.004798:0.004253:0.004264:0.007398:0.004475:0.004425:0.002167:0.004798:0.004778:0.002167:0.004808:0.002278:0.002832:0.002228:0.004667:0.004667:0.004425:0.006723:0.002278:0.002852:0.004667:0.002419
perindopril on left ventricular remodelling and clinical outcome. Results of the randomized perindopril and remodelling in elderly with acute myocardial infarction (PREAMI) study”. :@0.078621:0.942166:0.789790:0.942166:0.789790:0.933361:0.078621:0.933361:0.004848:0.004626:0.003205:0.002167:0.004828:0.004858:0.004667:0.004818:0.003205:0.002137:0.002056:0.003367:0.004667:0.004667:0.003367:0.002187:0.004697:0.003084:0.002611:0.003367:0.004183:0.004626:0.004888:0.002852:0.003205:0.002207:0.004435:0.004778:0.002197:0.004677:0.002983:0.003367:0.003175:0.004586:0.007428:0.004687:0.004818:0.004606:0.002137:0.002137:0.002167:0.004818:0.004667:0.003367:0.004677:0.004828:0.004667:0.003367:0.004415:0.002137:0.002167:0.004778:0.002207:0.004526:0.004657:0.002056:0.003367:0.004647:0.004909:0.002812:0.004505:0.004626:0.007398:0.004576:0.002419:0.003367:0.005463:0.004677:0.004274:0.004778:0.002268:0.002923:0.004102:0.003377:0.004687:0.002611:0.003367:0.002852:0.004818:0.004475:0.003367:0.003256:0.004677:0.004828:0.004858:0.004626:0.007358:0.002157:0.004012:0.004657:0.004667:0.003367:0.004848:0.004626:0.003205:0.002167:0.004828:0.004858:0.004667:0.004818:0.003205:0.002137:0.002056:0.003367:0.004677:0.004828:0.004667:0.003367:0.003185:0.004586:0.007428:0.004687:0.004818:0.004606:0.002137:0.002137:0.002167:0.004818:0.004667:0.003367:0.002167:0.004667:0.003367:0.004606:0.002197:0.004818:0.004626:0.003205:0.002238:0.004092:0.003367:0.006723:0.002278:0.002852:0.004667:0.003367:0.004626:0.004435:0.004909:0.002792:0.004475:0.003367:0.007358:0.004223:0.004707:0.004526:0.004677:0.003205:0.004778:0.002197:0.004657:0.002056:0.003367:0.002167:0.004888:0.002852:0.004677:0.003205:0.004566:0.002832:0.002228:0.004667:0.004667:0.003367:0.003115:0.005211:0.005624:0.005312:0.005513:0.007439:0.002742:0.002429:0.003367:0.004385:0.002852:0.004828:0.004878:0.004284:0.003699:0.002419:0.002419
Arch Intern Med:@0.790747:0.942166:0.853078:0.942166:0.853078:0.933361:0.790747:0.933361:0.005282:0.002852:0.004405:0.004667:0.003367:0.002288:0.004707:0.002651:0.004606:0.002893:0.004667:0.003367:0.007308:0.004606:0.004667
 2006;166:659-666. :@0.853078:0.942166:0.938037:0.942166:0.938037:0.933361:0.853078:0.933361:0.003367:0.005140:0.005241:0.005241:0.005392:0.002379:0.004677:0.005231:0.005342:0.003044:0.005211:0.005120:0.005251:0.003971:0.005231:0.005231:0.005050:0.002419:0.002419
3) :@0.078621:0.951241:0.089405:0.951241:0.089405:0.942120:0.078621:0.942120:0.005382:0.002983:0.002419
PROGRESS Collaborative Group. “Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack”. :@0.089879:0.951149:0.813154:0.951149:0.813154:0.942343:0.089879:0.942343:0.005211:0.005503:0.005886:0.005796:0.005624:0.005040:0.005473:0.005040:0.002903:0.005604:0.004647:0.002137:0.002197:0.004677:0.004888:0.004667:0.003256:0.004677:0.002832:0.002238:0.004183:0.004475:0.002903:0.005695:0.003215:0.004657:0.004798:0.004727:0.002419:0.002903:0.004334:0.005493:0.004677:0.004828:0.004858:0.004626:0.007358:0.002207:0.004314:0.004657:0.004667:0.002903:0.002852:0.003205:0.002197:0.004657:0.002056:0.002903:0.004687:0.002611:0.002903:0.004475:0.002903:0.004848:0.004626:0.003205:0.002167:0.004828:0.004858:0.004667:0.004818:0.003205:0.002137:0.002238:0.003760:0.004858:0.004727:0.004314:0.004657:0.004667:0.002903:0.004808:0.002228:0.004717:0.004687:0.004878:0.003760:0.004818:0.003175:0.004677:0.004374:0.004274:0.004798:0.003175:0.004747:0.003739:0.002228:0.004616:0.006642:0.004626:0.003205:0.002167:0.004818:0.004667:0.002903:0.003175:0.004657:0.004778:0.002127:0.007398:0.004626:0.004667:0.002903:0.004637:0.007428:0.004667:0.004818:0.004667:0.002903:0.005020:0.004667:0.005161:0.004838:0.002903:0.002167:0.004828:0.004778:0.002238:0.004274:0.002197:0.004798:0.004828:0.004647:0.002207:0.004102:0.002903:0.006723:0.002278:0.002852:0.004667:0.002903:0.004818:0.003175:0.004596:0.004274:0.002228:0.004657:0.004848:0.004102:0.002903:0.004385:0.002852:0.003215:0.004667:0.004576:0.004475:0.002903:0.004667:0.002983:0.002903:0.002852:0.003256:0.004677:0.004838:0.004253:0.002187:0.004626:0.004888:0.002611:0.002903:0.002207:0.004334:0.004435:0.004818:0.004606:0.004586:0.007358:0.002207:0.004294:0.002903:0.004677:0.003094:0.002933:0.004626:0.004435:0.004626:0.003699:0.002419:0.002419
The Lancet:@0.813638:0.951149:0.855749:0.951149:0.855749:0.942343:0.813638:0.942343:0.004576:0.004768:0.004475:0.002903:0.004445:0.004606:0.004788:0.004415:0.004526:0.002611
 2001;358:1033-41. :@0.855709:0.951149:0.938178:0.951149:0.938178:0.942343:0.855709:0.942343:0.002903:0.005140:0.005241:0.005030:0.004949:0.002873:0.005191:0.005201:0.005352:0.002369:0.004667:0.005171:0.005201:0.005140:0.003891:0.004747:0.004566:0.002419:0.002419
4) :@0.078621:0.960223:0.089365:0.960223:0.089365:0.951103:0.078621:0.951103:0.005342:0.002983:0.002419
Guerin AP, :@0.089365:0.960131:0.131376:0.960131:0.131376:0.951326:0.089365:0.951326:0.005685:0.004818:0.004626:0.003205:0.002167:0.004667:0.002419:0.005523:0.004062:0.002419:0.002419
et al.:@0.131376:0.960131:0.150013:0.960131:0.150013:0.951326:0.131376:0.951326:0.004526:0.002611:0.002419:0.004586:0.002076:0.002419
 “Impact of Aortic Stiffness Attenuation on Survival of Patients in End-Stage Renal Failure”. :@0.150013:0.960131:0.503919:0.960131:0.503919:0.951326:0.150013:0.951326:0.002419:0.004344:0.002258:0.007388:0.004848:0.004626:0.004566:0.002611:0.002419:0.004687:0.002611:0.002419:0.005352:0.004667:0.003467:0.002832:0.002207:0.004294:0.002419:0.005413:0.002832:0.002278:0.003084:0.002852:0.004818:0.004677:0.004374:0.004102:0.002419:0.005261:0.003094:0.002792:0.004626:0.004788:0.004828:0.004677:0.002832:0.002228:0.004667:0.004667:0.002419:0.004667:0.004667:0.002419:0.005261:0.004798:0.003437:0.004274:0.002238:0.004243:0.004657:0.002056:0.002419:0.004687:0.002611:0.002419:0.005130:0.004677:0.002832:0.002187:0.004626:0.004888:0.002923:0.004102:0.002419:0.002167:0.004667:0.002419:0.004919:0.004828:0.004878:0.003830:0.005413:0.002933:0.004616:0.004818:0.004475:0.002419:0.005463:0.004626:0.004818:0.004657:0.002056:0.002419:0.004737:0.004657:0.002137:0.002157:0.004798:0.003175:0.004485:0.003699:0.002419:0.002419
Circulation:@0.503919:0.960131:0.544388:0.960131:0.544388:0.951326:0.503919:0.951326:0.005423:0.002177:0.002852:0.004385:0.004778:0.002177:0.004526:0.002691:0.002177:0.004616:0.004667
 2001;103;987-992. :@0.544398:0.960131:0.626605:0.960131:0.626605:0.951326:0.544398:0.951326:0.002419:0.005140:0.005241:0.005030:0.004949:0.002379:0.004667:0.005171:0.005392:0.003024:0.005191:0.005050:0.004505:0.003790:0.005231:0.005171:0.005020:0.002419:0.002419
PAI594/04/2019.:@0.626605:0.960223:0.696818:0.960223:0.696818:0.951103:0.626605:0.951103:0.005181:0.005917:0.002863:0.005130:0.005272:0.005292:0.003840:0.005251:0.005292:0.003770:0.005171:0.005110:0.004667:0.005040:0.002419
Perindopril has proven outcomes in::@0.093769:0.524164:0.400904:0.524164:0.400904:0.507308:0.093769:0.507308:0.011138:0.010298:0.007022:0.005073:0.010466:0.011339:0.011154:0.011339:0.007022:0.005073:0.005073:0.005040:0.010466:0.009945:0.008433:0.005040:0.011339:0.006770:0.010651:0.009575:0.010298:0.010466:0.005040:0.011154:0.010466:0.006720:0.009340:0.011154:0.015959:0.010298:0.008433:0.005040:0.005073:0.010466:0.004972
• Coronary Artery Disease:@0.093769:0.540161:0.311282:0.540161:0.311282:0.524280:0.093769:0.524280:0.008030:0.005040:0.012230:0.010852:0.006434:0.010852:0.010348:0.009727:0.006804:0.009928:0.005040:0.013271:0.006804:0.006535:0.009945:0.006804:0.009928:0.005040:0.013137:0.004418:0.008366:0.009945:0.009727:0.008366:0.009945
1:@0.311279:0.534584:0.314785:0.534584:0.314785:0.525325:0.311279:0.525325:0.003506
• Acute Myocardial Infarction:@0.093769:0.556838:0.335842:0.556838:0.335842:0.540956:0.093769:0.540956:0.008030:0.005040:0.012851:0.009592:0.010348:0.006535:0.009945:0.005040:0.014581:0.009424:0.010852:0.009592:0.009727:0.006451:0.011154:0.004418:0.009727:0.004418:0.005040:0.004888:0.010348:0.005913:0.009727:0.006434:0.009592:0.006787:0.004418:0.010852:0.010348
2:@0.335839:0.551261:0.341705:0.551261:0.341705:0.542002:0.335839:0.542002:0.005867
• Stroke:@0.093769:0.573515:0.160662:0.573515:0.160662:0.557633:0.093769:0.557633:0.008030:0.005040:0.010667:0.006787:0.006434:0.010852:0.009139:0.009945
3:@0.160662:0.567938:0.166666:0.567938:0.166666:0.558679:0.160662:0.558679:0.006004
• End-stage Renal Failure:@0.093769:0.590191:0.304646:0.590191:0.304646:0.574310:0.093769:0.574310:0.008030:0.005040:0.011255:0.010348:0.011154:0.006854:0.008198:0.006787:0.009727:0.011154:0.009945:0.005040:0.011978:0.009945:0.010348:0.009727:0.004418:0.005040:0.010600:0.009727:0.004418:0.004418:0.010348:0.006434:0.009945
4:@0.304643:0.584614:0.311215:0.584614:0.311215:0.575355:0.304643:0.575355:0.006572
Need :@0.096837:0.180416:0.220127:0.180416:0.220127:0.142301:0.096837:0.142301:0.033060:0.025077:0.025077:0.027980:0.012095
endurance:@0.219224:0.182048:0.443026:0.182048:0.452367:0.141592:0.228565:0.141592:0.025924:0.026327:0.028424:0.026327:0.017054:0.025077:0.026327:0.023626:0.034056
when treating CVS disease?:@0.096837:0.217361:0.678617:0.217361:0.678617:0.179246:0.096837:0.179246:0.035923:0.026045:0.025077:0.026045:0.012095:0.017498:0.016651:0.025077:0.024352:0.017498:0.011813:0.026045:0.027980:0.012095:0.030923:0.030440:0.027013:0.012095:0.027980:0.011813:0.021288:0.025077:0.024553:0.021288:0.023465:0.021650
the :@0.078610:0.869301:0.118968:0.869301:0.118968:0.850243:0.078610:0.850243:0.008749:0.013023:0.012539:0.006048
endurance:@0.118517:0.870117:0.230418:0.870117:0.235088:0.849889:0.123187:0.849889:0.012962:0.013164:0.014212:0.013164:0.008527:0.012539:0.013164:0.011813:0.017028
ACE-inhibitor:@0.238729:0.869301:0.380848:0.869301:0.380848:0.850243:0.238729:0.850243:0.015704:0.015482:0.014111:0.008830:0.005907:0.013023:0.013023:0.005907:0.013990:0.005907:0.008447:0.013627:0.008164
PAI594/04/2019_HandbookFP_21May2019.indd   1:@0.023981:1.017923:0.254828:1.017923:0.254828:1.009401:0.023981:1.009401:0.006723:0.006723:0.002802:0.005604:0.005604:0.005604:0.002802:0.005604:0.005604:0.002802:0.005604:0.005604:0.005604:0.005604:0.005604:0.007277:0.005604:0.005604:0.005604:0.005604:0.005604:0.005604:0.005040:0.006158:0.006723:0.005604:0.005604:0.005604:0.008396:0.005604:0.005040:0.005604:0.005604:0.005604:0.005604:0.002802:0.002238:0.005604:0.005604:0.005604:0.002802:0.002802:0.002802:0.005604
2019/05/21   13:55:@0.916467:1.017923:1.000529:1.017923:1.000529:1.009401:0.916467:1.009401:0.005604:0.005604:0.005604:0.005604:0.002802:0.005604:0.005604:0.002802:0.005604:0.005604:0.002802:0.002802:0.002802:0.005604:0.005604:0.002802:0.005604:0.005604